https://scholars.lib.ntu.edu.tw/handle/123456789/494944
標題: | Scientific Advances in Thoracic Oncology 2016 | 作者: | Soo R.A Stone E.C.A Cummings K.M Jett J.R Field J.K Groen H.J.M Mulshine J.L Yatabe Y Bubendorf L Dacic S Rami-Porta R Detterbeck F.C Lim E Asamura H Donington J Wakelee H.A Wu Y.-L Higgins K Senan S Solomon B Kim D.-W Johnson M CHIH-HSIN YANG Sequist L.V Shaw A.T Ahn M.-J Costa D.B Patel J.D Horn L Gettinger S Peters S Wynes M.W Faivre-Finn C Rudin C.M Tsao A Baas P Kelly R.J Leighl N.B Scagliotti G.V Gandara D.R Hirsch F.R Spigel D.R. |
關鍵字: | Adjuvant therapy; Biomarkers; Cancer prevention; Immunotherapy; Malignant mesothelioma; Molecular diagnostics; NSCLC; Pathology; Radiotherapy; SCLC; Screening; Smoking cessation; Staging; Surgery; Targeted therapy; Value of therapy | 公開日期: | 2017 | 出版社: | Elsevier Inc | 卷: | 12 | 期: | 8 | 起(迄)頁: | 1183-1209 | 來源出版物: | Journal of Thoracic Oncology | 摘要: | Lung cancer care is rapidly changing with advances in genomic testing, the development of next-generation targeted kinase inhibitors, and the continued broad study of immunotherapy in new settings and potential combinations. The International Association for the Study of Lung Cancer and the Journal of Thoracic Oncology publish this annual update to help readers keep pace with these important developments. Experts in thoracic cancer and care provide focused updates across multiple areas, including prevention and early detection, molecular diagnostics, pathology and staging, surgery, adjuvant therapy, radiotherapy, molecular targeted therapy, and immunotherapy for NSCLC, SCLC, and mesothelioma. Quality and value of care and perspectives on the future of lung cancer research and treatment have also been included in this concise review. ? 2017 International Association for the Study of Lung Cancer |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85030094918&doi=10.1016%2fj.jtho.2017.05.019&partnerID=40&md5=e9088218606a71ae2f0848db276016f9 https://scholars.lib.ntu.edu.tw/handle/123456789/494944 |
ISSN: | 1556-0864 | DOI: | 10.1016/j.jtho.2017.05.019 | SDG/關鍵字: | afatinib; alectinib; atezolizumab; avelumab; bevacizumab; brigatinib; carboplatin; ceritinib; cisplatin; crizotinib; dabrafenib; docetaxel; durvalumab; erlotinib; etoposide; gefitinib; gemcitabine; icotinib; ipilimumab; lorlatinib; nivolumab; osimertinib; pembrolizumab; pemetrexed; placebo; ticilimumab; trametinib; unindexed drug; vemurafenib; vinorelbine tartrate; adjuvant therapy; brain metastasis; cancer adjuvant therapy; cancer immunotherapy; cancer prevention; cancer resistance; cancer screening; cancer staging; cannabis use; chemoradiotherapy; computer assisted tomography; conformal radiotherapy; disease free survival; early cancer diagnosis; gene mutation; hemoptysis; human; intensity modulated radiation therapy; liquid biopsy; lung adenocarcinoma; lung cancer; lung lobectomy; mesothelioma; molecularly targeted therapy; multiple cycle treatment; neutropenia; non small cell lung cancer; oncogene; overall survival; pneumonia; priority journal; radiation pneumonia; radiosurgery; Review; robot assisted surgery; small cell lung cancer; smoking; stereotactic body radiation therapy; unspecified side effect; vaping; video assisted thoracoscopic surgery; whole brain radiotherapy; history; thorax tumor; History, 21st Century; Humans; Thoracic Neoplasms |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。